Generic selectors
Exact matches only
Search in title
Search in content
Filter by Categories


Vaccitech shoots for US IPO
Oxford spinout Vaccitech, which developed the technology underlying the university’s covid vaccine, has filed for an offering on the Nasdaq Global Market.
Coursera graduates to public markets in $519m IPO
The online learning platform developer spun out of Stanford University priced its shares at the top of their range.
Achilles ascends to Nasdaq
Achilles Therapeutics has raised more than $175m in its initial public offering on the Nasdaq Global Select Market.
Lilium lands on $3.3bn reverse merger
The vertical take-off and landing jet developer, an Unternehmertum spinout, is joining forces with the Nasdaq-listed Qell Acquisition Corp.
Lava breaks through to public markets
Lava Therapeutics, which is developing cancer treatments based on research at Amsterdam University Medical Centers, floated in a $101m offering.
Akoya acts to file for $115m IPO
The tissue analysis device maker, a spinout from Stanford University, has selected the Nasdaq Global Select Market for its initial public offering.
Recursion takes steps toward IPO
The University of Utah spinout is looking to float on the Nasdaq Global Select Market and has filed with a $100m placeholder amount.
Visional to visit public markets
Tokyo University of Science is set to exit the recruitment services group in an IPO in Tokyo.

Other News

Design Therapeutics drafts IPO filing
UW Madison’s small-molecule therapy spinout has raised $170m in venture funding since emerging from stealth less than a year ago.
Coursera to class as public company
University of Pennyslvania and Caltech are in line for exits when Stanford’s online education spinout lists on the New York Stock Exchange.
Lava Therapeutics flows toward public markets
Immuno-oncology therapy developer Lava Therapeutics has filed for a $100m IPO, having been set up in 2016 to exploit Amsterdam University Medical Centers research.
Talis takes in IPO proceeds
Caltech spinout Talis Biomedical has raised more than $220m in an initial public offering on the Nasdaq Global Market.
NexImmune collects IPO proceeds
NexImmune priced shares at $17 to raise $110m in an upsized offering, enabling Amgen and Pfizer to exit the Johns Hopkins University spinout.
Vor Biopharma forces through $177m IPO
The share price of Columbia University's cellular oncology drug developer, backed by Osage University Partners, has doubled since it floated.

Editor's Picks

Big deal: Orchard harvests $200m IPO
Orchard Therapeutics has listed in the US following a $200m initial public offering that came just three years after the gene therapy developer was spun out of UCL.
Big deal: Nucana and Nightstar race to public markets
Nucana, a Scottish Investment Bank-backed cancer treatment developer, and Nightstar Therapeutics, an Oxford spinout focused on retinal gene therapies, have entered the public market.
test reg